Autologous fibroblast injection: second-session patient journey

A real-world case documenting a second autologous-fibroblast-related skin injection in a client aged 50+, with evidence boundaries explained.

What was documented

According to the service record, the client returned roughly one month after a first session for a second injection. The clinic described the procedure as an autologous-fibroblast-related skin treatment.

Medical context and evidence limits

The client reported perceived changes in skin texture, fullness and clarity. These are subjective observations and do not by themselves establish medical efficacy. Manufacturing, cell quality, indications, regulatory status and clinical evidence can vary by product and provider.

What to check before treatment

Before considering a cell-related cosmetic or regenerative procedure, patients should verify cell source, manufacturing facility, treating institution, regulatory or notification status, risks and individual medical suitability.